Relapsed/Refractory Diffuse Large B-Cell Lymphoma - A Breakthrough in CD20 CAR-T Preemptive Therapy. the team of Directors Ke Xiaoyan and Hu Kai from the Department of Lymphoma and Myeloma at Beijing Gobroad Hospital published a study titled "CD20 CAR-T Therapy Preemptively Treats Patients with Relapsed/Refractory DLBCL in Partial Remission after CD19 CAR-T" in the journal Transplant and Cellular Therapy.
